Thomas Kuhn began his career with Merck KGaA in 2000 where he held various positions in clinical development, mainly in the therapeutic area of Type 2 diabetes and was responsible, in particular, for forging partnerships with Japanese pharmaceutical companies. Between 2004 and 2007, he directed Merck’s global R&D projects with two products in Phase 2 clinical trials and all the life cycle management projects primarily for Glucophage®, the current reference in diabetes treatment. Following Merck’s acquisition of Serono in 2007, Thomas Kuhn was part of the team which refined Merck Serono’s strategy for divesting from the diabetes therapeutic area. Thomas Kuhn initiated and concluded the project for the transfer of Merck Serono’s assets under development in Diabetes to a new legal entity called Poxel. Since this transfer, Thomas Kuhn has been Poxel’s Chief Executive Officer. Mr. Kuhn holds a pharmacy degree from the University of Lyon I (France) and an MBA from Ashridge Business School (UK) of Medicine. 

Sylvie joined Poxel in 2021. She has 20 years of Human Resources experience in various industries and services. After a few years as a mathematics teacher, Sylvie quickly turned to the HR profession by joining USG People as a recruitment agency manager for 9 years. She then joined Sabert Corporation Europe as HR Director for 7 years, where she defined and implemented the European Human Resources strategy in a context of rapid growth. Prior to joining the Company, Sylvie was HR Director at Thermo Fisher (previously Novasep) and spent almost 4 years leading the Human Resources function of the European biopharma activities for the Group. Sylvie brings strong expertise in supporting growing companies and implementing HR strategies, processes, and forward-looking management to support their development.

Sylvie holds a Master's degree in mathematics.

Graduating with a Master's degree in Audit and Control from IAE Grenoble, a Bachelor's degree in Business Management and Administration from the University of Bristol and a DUT in Business and Administration Management, she joined Poxel's finance team in October 2016 after starting her career in Audit at Mazars and then Owens Corning, where she was successively in charge of Management Control for the Research & Development center and then the financial analysis of the group's European production and sales activities.

Tejdeep joined Poxel in 2018, and most recently, in May 2023, was appointed Vice President and Head of Business Development, having previously held the positions of Director and Senior Director BD.

Prior to joining Poxel, Tejdeep was a Senior Consultant at Back Bay Life Science Advisors in Boston from 2015- 2018, where he worked at the intersection of strategy consulting and financial advisory and advised a broad spectrum of life science clients, ranging from early-stage to large pharmaceutical and medical device companies on global engagements ranging from asset-specific issues to corporate level strategy, buy / sell side diligence, and M&A and licensing strategy. Tejdeep started his professional career in 2013 at IMS Consulting Group in New York (now IQVIA), where he advised top 10 pharma and large biotech globally on commercialization / launch strategy, portfolio analysis, brand and pricing and market access strategy.

Tejdeep received his MBA from The Wharton School, University of Pennsylvania, M.A. in Computational Biology from Columbia University, New York, and B.Tech in Computer Science & Engineering from GGSIP University, New Delhi